ReviewCancer innovation2026
Clinical Advances in Breast Cancer: A Comprehensive Overview of Full-Course Disease Management.
Review in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Advances in Breast Cancer: A Comprehensive Overview of Full-Course Disease Management.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of breast cancer (BC) treatment has reached a pivotal turning point in recent years, marked by a succession of breakthrough findings from landmark international clinical trials. These advances have fundamentally reshaped treatment paradigms across distinct molecular subtypes. In the field of hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2-negative (HER2-negative) BC, the introduction of novel targeted agents has continuously optimized therapeutic strategies. Meanwhile, the management of endocrine therapy resistance has evolved into an innovative framework characterized by multitarget therapeutic combination approaches. Concurrently, the extensive impact of the DESTINY-Breast series has constructed a stratified, precision medicine system covering the entire disease course of HER2-positive BC. In triple-negative breast cancer, the ASCENT-03 and ASCENT-04 trials have successfully positioned antibody-drug conjugates as a cornerstone of first-line treatment for advanced disease. This article focuses on the latest advances in BC, systematically reviewing recent clinical evidence and practical experience in medical oncology to provide a robust reference for clinical diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.